vs
康宝莱（HLF）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
康宝莱的季度营收约是Revvity的1.7倍（$1.3B vs $772.1M），Revvity净利率更高（12.7% vs 6.7%，领先6.1%），康宝莱同比增速更快（6.3% vs 5.9%），Revvity自由现金流更多（$161.8M vs $79.8M），过去两年Revvity的营收复合增速更高（9.0% vs 0.7%）
康宝莱是美国跨国多层次营销企业，主营膳食补充剂的研发与销售。该公司曾被指控涉嫌金字塔骗局欺诈运营，2016年与美国证监会达成协议后调整了薪酬体系，将经销商奖励与可核实的实际销售额挂钩。此外其部分产品曾被曝出引发急性肝炎的相关问题。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
HLF vs RVTY — 直观对比
营收规模更大
HLF
是对方的1.7倍
$772.1M
营收增速更快
HLF
高出0.4%
5.9%
净利率更高
RVTY
高出6.1%
6.7%
自由现金流更多
RVTY
多$82.0M
$79.8M
两年增速更快
RVTY
近两年复合增速
0.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.3B | $772.1M |
| 净利润 | $85.4M | $98.4M |
| 毛利率 | 77.5% | — |
| 营业利润率 | 7.8% | 14.5% |
| 净利率 | 6.7% | 12.7% |
| 营收同比 | 6.3% | 5.9% |
| 净利润同比 | -52.0% | 3.9% |
| 每股收益（稀释后） | $0.81 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HLFRVTY
| Q4 25 | $1.3B | $772.1M | ||
| Q3 25 | $1.3B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.2B | $729.4M | ||
| Q3 24 | $1.2B | $684.0M | ||
| Q2 24 | $1.3B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润HLFRVTY
| Q4 25 | $85.4M | $98.4M | ||
| Q3 25 | $43.2M | $46.7M | ||
| Q2 25 | $49.3M | $53.9M | ||
| Q1 25 | $50.4M | $42.2M | ||
| Q4 24 | $177.9M | $94.6M | ||
| Q3 24 | $47.4M | $94.4M | ||
| Q2 24 | $4.7M | $55.4M | ||
| Q1 24 | $24.3M | $26.0M |
毛利率HLFRVTY
| Q4 25 | 77.5% | — | ||
| Q3 25 | 77.7% | 53.6% | ||
| Q2 25 | 78.0% | 54.5% | ||
| Q1 25 | 78.3% | 56.5% | ||
| Q4 24 | 77.8% | — | ||
| Q3 24 | 78.3% | 56.3% | ||
| Q2 24 | 77.9% | 55.7% | ||
| Q1 24 | 77.5% | 54.6% |
营业利润率HLFRVTY
| Q4 25 | 7.8% | 14.5% | ||
| Q3 25 | 9.9% | 11.7% | ||
| Q2 25 | 10.5% | 12.6% | ||
| Q1 25 | 10.1% | 10.9% | ||
| Q4 24 | 8.8% | 16.3% | ||
| Q3 24 | 10.2% | 14.3% | ||
| Q2 24 | 6.3% | 12.4% | ||
| Q1 24 | 5.7% | 6.8% |
净利率HLFRVTY
| Q4 25 | 6.7% | 12.7% | ||
| Q3 25 | 3.4% | 6.7% | ||
| Q2 25 | 3.9% | 7.5% | ||
| Q1 25 | 4.1% | 6.4% | ||
| Q4 24 | 14.7% | 13.0% | ||
| Q3 24 | 3.8% | 13.8% | ||
| Q2 24 | 0.4% | 8.0% | ||
| Q1 24 | 1.9% | 4.0% |
每股收益（稀释后）HLFRVTY
| Q4 25 | $0.81 | $0.86 | ||
| Q3 25 | $0.42 | $0.40 | ||
| Q2 25 | $0.48 | $0.46 | ||
| Q1 25 | $0.49 | $0.35 | ||
| Q4 24 | $1.75 | $0.77 | ||
| Q3 24 | $0.46 | $0.77 | ||
| Q2 24 | $0.05 | $0.45 | ||
| Q1 24 | $0.24 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $353.1M | $919.9M |
| 总债务越低越好 | $2.0B | — |
| 股东权益账面价值 | $-515.1M | $7.3B |
| 总资产 | $2.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HLFRVTY
| Q4 25 | $353.1M | $919.9M | ||
| Q3 25 | $305.5M | $931.4M | ||
| Q2 25 | $320.9M | $991.8M | ||
| Q1 25 | $329.4M | $1.1B | ||
| Q4 24 | $415.3M | $1.2B | ||
| Q3 24 | $402.5M | $1.2B | ||
| Q2 24 | $374.0M | $2.0B | ||
| Q1 24 | $398.3M | $1.7B |
总债务HLFRVTY
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.3B | — | ||
| Q1 24 | $2.4B | — |
股东权益HLFRVTY
| Q4 25 | $-515.1M | $7.3B | ||
| Q3 25 | $-612.0M | $7.4B | ||
| Q2 25 | $-660.5M | $7.6B | ||
| Q1 25 | $-736.0M | $7.6B | ||
| Q4 24 | $-801.1M | $7.7B | ||
| Q3 24 | $-954.2M | $7.9B | ||
| Q2 24 | $-1.0B | $7.9B | ||
| Q1 24 | $-1.0B | $7.8B |
总资产HLFRVTY
| Q4 25 | $2.8B | $12.2B | ||
| Q3 25 | $2.7B | $12.1B | ||
| Q2 25 | $2.7B | $12.4B | ||
| Q1 25 | $2.7B | $12.4B | ||
| Q4 24 | $2.7B | $12.4B | ||
| Q3 24 | $2.7B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B | ||
| Q1 24 | $2.6B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $79.8M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.2% | 21.0% |
| 资本支出强度资本支出/营收 | 1.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.15× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $252.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流HLFRVTY
| Q4 25 | $98.3M | $182.0M | ||
| Q3 25 | $138.8M | $138.5M | ||
| Q2 25 | $96.0M | $134.3M | ||
| Q1 25 | $200.0K | $128.2M | ||
| Q4 24 | $69.6M | $174.2M | ||
| Q3 24 | $99.5M | $147.9M | ||
| Q2 24 | $102.5M | $158.6M | ||
| Q1 24 | $13.8M | $147.6M |
自由现金流HLFRVTY
| Q4 25 | $79.8M | $161.8M | ||
| Q3 25 | $118.0M | $120.0M | ||
| Q2 25 | $73.2M | $115.5M | ||
| Q1 25 | $-18.1M | $112.2M | ||
| Q4 24 | $43.9M | $149.8M | ||
| Q3 24 | $72.4M | $125.6M | ||
| Q2 24 | $66.2M | $136.6M | ||
| Q1 24 | $-19.1M | $129.7M |
自由现金流率HLFRVTY
| Q4 25 | 6.2% | 21.0% | ||
| Q3 25 | 9.3% | 17.2% | ||
| Q2 25 | 5.8% | 16.0% | ||
| Q1 25 | -1.5% | 16.9% | ||
| Q4 24 | 3.6% | 20.5% | ||
| Q3 24 | 5.8% | 18.4% | ||
| Q2 24 | 5.2% | 19.7% | ||
| Q1 24 | -1.5% | 20.0% |
资本支出强度HLFRVTY
| Q4 25 | 1.4% | 2.6% | ||
| Q3 25 | 1.6% | 2.6% | ||
| Q2 25 | 1.8% | 2.6% | ||
| Q1 25 | 1.5% | 2.4% | ||
| Q4 24 | 2.1% | 3.4% | ||
| Q3 24 | 2.2% | 3.3% | ||
| Q2 24 | 2.8% | 3.2% | ||
| Q1 24 | 2.6% | 2.7% |
现金转化率HLFRVTY
| Q4 25 | 1.15× | 1.85× | ||
| Q3 25 | 3.21× | 2.97× | ||
| Q2 25 | 1.95× | 2.49× | ||
| Q1 25 | 0.00× | 3.03× | ||
| Q4 24 | 0.39× | 1.84× | ||
| Q3 24 | 2.10× | 1.57× | ||
| Q2 24 | 21.81× | 2.87× | ||
| Q1 24 | 0.57× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HLF
| Others | $514.4M | 40% |
| Other | $300.0M | 23% |
| IN | $250.3M | 20% |
| MX | $147.2M | 11% |
| VN | $71.1M | 6% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
